Mesenchymal stromal cells improve renovascular function in polycystic kidney disease

Federico Franchi, Karen M. Peterson, Rende Xu, Brent Miller, Peter J. Psaltis, Peter C Harris, Lilach O Lerman, Martin G Rodriguez-Porcel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Polycystic kidney disease (PKD) is a common cause of end-stage renal failure, for which there is no accepted treatment. Progenitor and stem cells have been shown to restore renal function in a model of renovascular disease, a disease that shares many features with PKD. The objective of this study was to examine the potential of adult stem cells to restore renal structure and function in PKD. Bone marrow-derived mesenchymal stromal cells (MSCs, 2.5 ´ 10<sup>5</sup>) were intrarenally infused in 6-week-old PCK rats. At 10 weeks of age, PCK rats had an increase in systolic blood pressure (SBP) versus controls (126.22 ± 2.74 vs. 116.45 ± 3.53 mmHg, p < 0.05) and decreased creatinine clearance (3.76 ± 0.31 vs. 6.10 ± 0.48 μl/min/g, p < 0.01), which were improved in PKD animals that received MSCs (SBP: 114.67 ± 1.34 mmHg, and creatinine clearance: 4.82 ± 0.24 μl/min/g, p = 0.001 and p = 0.003 vs. PKD, respectively). MSCs preserved vascular density and glomeruli diameter, measured using microcomputed tomography. PCK animals had increased urine osmolality (843.9 ± 54.95 vs. 605.6 ± 45.34 mOsm, p < 0.01 vs. control), which was improved after MSC infusion and not different from control (723.75 ± 56.6 mOsm, p = 0.13 vs. control). Furthermore, MSCs reduced fibrosis and preserved the expression of proangiogenic molecules, while cyst size and number were unaltered by MSCs. Delivery of exogenous MSCs improved vascular density and renal function in PCK animals, and the benefit was observed up to 4 weeks after a single infusion. Cell-based therapy constitutes a novel approach in PKD.

Original languageEnglish (US)
Pages (from-to)1687-1698
Number of pages12
JournalCell Transplantation
Volume24
Issue number9
DOIs
StatePublished - Sep 14 2015

Fingerprint

Polycystic Kidney Diseases
Mesenchymal Stromal Cells
Blood Pressure
Kidney
Animals
Blood Vessels
Creatinine
Blood pressure
Stem Cells
Stem cells
Rats
X-Ray Microtomography
Adult Stem Cells
Cell- and Tissue-Based Therapy
Osmolar Concentration
Chronic Kidney Failure
Pressure control
Cysts
Fibrosis
Bone Marrow

Keywords

  • Kidney
  • Mesenchymal stromal cells (MSCs)
  • Polycystic kidney disease (PKD)
  • Renal function
  • Vasculature

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering

Cite this

Mesenchymal stromal cells improve renovascular function in polycystic kidney disease. / Franchi, Federico; Peterson, Karen M.; Xu, Rende; Miller, Brent; Psaltis, Peter J.; Harris, Peter C; Lerman, Lilach O; Rodriguez-Porcel, Martin G.

In: Cell Transplantation, Vol. 24, No. 9, 14.09.2015, p. 1687-1698.

Research output: Contribution to journalArticle

Franchi, Federico ; Peterson, Karen M. ; Xu, Rende ; Miller, Brent ; Psaltis, Peter J. ; Harris, Peter C ; Lerman, Lilach O ; Rodriguez-Porcel, Martin G. / Mesenchymal stromal cells improve renovascular function in polycystic kidney disease. In: Cell Transplantation. 2015 ; Vol. 24, No. 9. pp. 1687-1698.
@article{fc4e072189554d019612a0901eae62c7,
title = "Mesenchymal stromal cells improve renovascular function in polycystic kidney disease",
abstract = "Polycystic kidney disease (PKD) is a common cause of end-stage renal failure, for which there is no accepted treatment. Progenitor and stem cells have been shown to restore renal function in a model of renovascular disease, a disease that shares many features with PKD. The objective of this study was to examine the potential of adult stem cells to restore renal structure and function in PKD. Bone marrow-derived mesenchymal stromal cells (MSCs, 2.5 ´ 105) were intrarenally infused in 6-week-old PCK rats. At 10 weeks of age, PCK rats had an increase in systolic blood pressure (SBP) versus controls (126.22 ± 2.74 vs. 116.45 ± 3.53 mmHg, p < 0.05) and decreased creatinine clearance (3.76 ± 0.31 vs. 6.10 ± 0.48 μl/min/g, p < 0.01), which were improved in PKD animals that received MSCs (SBP: 114.67 ± 1.34 mmHg, and creatinine clearance: 4.82 ± 0.24 μl/min/g, p = 0.001 and p = 0.003 vs. PKD, respectively). MSCs preserved vascular density and glomeruli diameter, measured using microcomputed tomography. PCK animals had increased urine osmolality (843.9 ± 54.95 vs. 605.6 ± 45.34 mOsm, p < 0.01 vs. control), which was improved after MSC infusion and not different from control (723.75 ± 56.6 mOsm, p = 0.13 vs. control). Furthermore, MSCs reduced fibrosis and preserved the expression of proangiogenic molecules, while cyst size and number were unaltered by MSCs. Delivery of exogenous MSCs improved vascular density and renal function in PCK animals, and the benefit was observed up to 4 weeks after a single infusion. Cell-based therapy constitutes a novel approach in PKD.",
keywords = "Kidney, Mesenchymal stromal cells (MSCs), Polycystic kidney disease (PKD), Renal function, Vasculature",
author = "Federico Franchi and Peterson, {Karen M.} and Rende Xu and Brent Miller and Psaltis, {Peter J.} and Harris, {Peter C} and Lerman, {Lilach O} and Rodriguez-Porcel, {Martin G}",
year = "2015",
month = "9",
day = "14",
doi = "10.3727/096368914X684619",
language = "English (US)",
volume = "24",
pages = "1687--1698",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "9",

}

TY - JOUR

T1 - Mesenchymal stromal cells improve renovascular function in polycystic kidney disease

AU - Franchi, Federico

AU - Peterson, Karen M.

AU - Xu, Rende

AU - Miller, Brent

AU - Psaltis, Peter J.

AU - Harris, Peter C

AU - Lerman, Lilach O

AU - Rodriguez-Porcel, Martin G

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Polycystic kidney disease (PKD) is a common cause of end-stage renal failure, for which there is no accepted treatment. Progenitor and stem cells have been shown to restore renal function in a model of renovascular disease, a disease that shares many features with PKD. The objective of this study was to examine the potential of adult stem cells to restore renal structure and function in PKD. Bone marrow-derived mesenchymal stromal cells (MSCs, 2.5 ´ 105) were intrarenally infused in 6-week-old PCK rats. At 10 weeks of age, PCK rats had an increase in systolic blood pressure (SBP) versus controls (126.22 ± 2.74 vs. 116.45 ± 3.53 mmHg, p < 0.05) and decreased creatinine clearance (3.76 ± 0.31 vs. 6.10 ± 0.48 μl/min/g, p < 0.01), which were improved in PKD animals that received MSCs (SBP: 114.67 ± 1.34 mmHg, and creatinine clearance: 4.82 ± 0.24 μl/min/g, p = 0.001 and p = 0.003 vs. PKD, respectively). MSCs preserved vascular density and glomeruli diameter, measured using microcomputed tomography. PCK animals had increased urine osmolality (843.9 ± 54.95 vs. 605.6 ± 45.34 mOsm, p < 0.01 vs. control), which was improved after MSC infusion and not different from control (723.75 ± 56.6 mOsm, p = 0.13 vs. control). Furthermore, MSCs reduced fibrosis and preserved the expression of proangiogenic molecules, while cyst size and number were unaltered by MSCs. Delivery of exogenous MSCs improved vascular density and renal function in PCK animals, and the benefit was observed up to 4 weeks after a single infusion. Cell-based therapy constitutes a novel approach in PKD.

AB - Polycystic kidney disease (PKD) is a common cause of end-stage renal failure, for which there is no accepted treatment. Progenitor and stem cells have been shown to restore renal function in a model of renovascular disease, a disease that shares many features with PKD. The objective of this study was to examine the potential of adult stem cells to restore renal structure and function in PKD. Bone marrow-derived mesenchymal stromal cells (MSCs, 2.5 ´ 105) were intrarenally infused in 6-week-old PCK rats. At 10 weeks of age, PCK rats had an increase in systolic blood pressure (SBP) versus controls (126.22 ± 2.74 vs. 116.45 ± 3.53 mmHg, p < 0.05) and decreased creatinine clearance (3.76 ± 0.31 vs. 6.10 ± 0.48 μl/min/g, p < 0.01), which were improved in PKD animals that received MSCs (SBP: 114.67 ± 1.34 mmHg, and creatinine clearance: 4.82 ± 0.24 μl/min/g, p = 0.001 and p = 0.003 vs. PKD, respectively). MSCs preserved vascular density and glomeruli diameter, measured using microcomputed tomography. PCK animals had increased urine osmolality (843.9 ± 54.95 vs. 605.6 ± 45.34 mOsm, p < 0.01 vs. control), which was improved after MSC infusion and not different from control (723.75 ± 56.6 mOsm, p = 0.13 vs. control). Furthermore, MSCs reduced fibrosis and preserved the expression of proangiogenic molecules, while cyst size and number were unaltered by MSCs. Delivery of exogenous MSCs improved vascular density and renal function in PCK animals, and the benefit was observed up to 4 weeks after a single infusion. Cell-based therapy constitutes a novel approach in PKD.

KW - Kidney

KW - Mesenchymal stromal cells (MSCs)

KW - Polycystic kidney disease (PKD)

KW - Renal function

KW - Vasculature

UR - http://www.scopus.com/inward/record.url?scp=84940776608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940776608&partnerID=8YFLogxK

U2 - 10.3727/096368914X684619

DO - 10.3727/096368914X684619

M3 - Article

VL - 24

SP - 1687

EP - 1698

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 9

ER -